Abstract: A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

Abstract: Compositions, food products, methods and systems for use in increasing the blood bioavailability of amino acids derived from proteins, preferably proteins of plant origin, comprising a mixture M comprising or, alternatively, consisting of at least one bacterial strain, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-S01™ DSM 26760, and possibly. The compositions food products, methods and systems o the disclosure, can further comprise at least one protein, preferably proteins of plant origin, or a peptide or an amino acid, and in particular includes a food product comprising proteins, preferably of plant origin, and said mixture M of at least one bacterial strain.

Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.

Abstract: Disclosed is a Lactobacillus strain having a blood glucose lowering effect and an antioxidant effect, a culture medium of the strain, and a cell-free supernatant of the strain. Further, a composition for lowering a blood glucose level contains the same. A composition having an antioxidant ability contains the same. The Lactobacillus plantarum MG4229 strain according to the present disclosure has excellent blood glucose lowering activity and antioxidant activity, and has excellent acid tolerance, bile tolerance, auto-aggregation, and adhesion to epithelial cells, and thus is suitable for probiotics, and thus may be used in various ways as a composition for preventing or treating diabetes mellitus or a composition having antioxidant ability.

Abstract: The invention pertains to methods and vaccines suitable for preventing or reducing malaria transmission. The vaccines block the interaction between ?-tubulin from a malarial parasite and FREP-1 from the mid-gut of a malaria carrier mosquito, for example, Anopheles gambiae.

Abstract: The present invention relates to expression of Pneumococcal Surface Protein A (PspA). The invention represents an advancement in the field of genetic engineering and vaccine technology. The invention discloses expression vectors and recombinant host cells for expression of truncated PspA peptide. The invention also discloses vaccine compositions comprising the truncated peptides as carrier protein.

Abstract: The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.

Abstract: Less-than-diploid I. orientalis cells are produced. The cells have at least one unpaired chromosome and may be haploid, i.e., are missing one member of each pair of chromosomes that are present in the wild-type strains. The less-than-diploid cells are useful fermentation strains, performing similarly to diploid strains that are otherwise similarly engineered. The less-than-diploid strains can be mated to produce diploids, which themselves are useful fermentation strains. The less-than-diploid strains are also useful as host strains for producing further genetically modified strains that can be less-than-diploid or mated to produce diploids.

Abstract: Disclosed herein are combinations of Yersinia entomophaga and/or Yersinia nurmii and/or toxins therefrom, with one or more of a variety of substances, including animal repellents, acaracides, antimicrobials, avicides, bactericides, biostimulants, disinfectants and/or sanitizers, fungicides, gastropodicides, herbicides, insecticides, insect growth regulators, insect repellents, miticides, molluscicides, nematicides, plant signal molecules, plant nutrients, plant fertilizers, predacides, piscicides, rodenticides, termiticides, viricides, and the like. The combinations may have additive effects or unexpected effects on pests, insects being one example, and/or on plant growth and/or plant yield. Also disclosed are methods for using the disclosed combinations.

Abstract: The present invention broadly provides different compositions, kits, vectors, and methods including monoclonal antibodies directed to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.

Abstract: The present application provides a modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The Brucella strain has been modified through an inactivation of the wzm gene. Further, the present application provides a pharmaceutical composition which comprises the modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The present application also provides a kit which comprises the modified Brucella strain and a pharmaceutically acceptable carrier or diluent and its use for the treatment and/or prevention of brucellosis.

Abstract: The present disclosure provides immunomodulatory compositions comprising live Caulobacter crescentus (CC). Immunomodulatory compositions of the present disclosure are useful for modulating an immune response in an individual. The present disclosure thus provides methods of modulating an immune response in an individual, involving administering an immunomodulatory composition comprising live CC to the individual.

Abstract: The present invention provides isolated proteins isolatable from a Pasteurella spp. such as P. multocida. Also provided by the present invention are compositions that include one or more of the proteins, and methods for making and methods for using the proteins.

Abstract: This invention relates to novel fusion peptides and immunogenic compositions containing the fusion peptides useful in the control and prevention of tick infestations. The invention also relates to compositions comprising said fusion peptides, methods of vaccination against tick infestation using said fusion peptides and compositions, and kits for use with such compositions and methods.

Abstract: The present invention relates to a use of a microorganism of the class Coriobacteriia for promoting gut health of a healthy subject. Also provided is a method for the production of chenodeoxycholic acid (CDCA) and a method for the production of lithocholic acid (LCA).

Abstract: The invention relates to mutant forms of CsgG. The invention also relates to analyte detection and characterization using CsgG.

Abstract: The invention relates to bacterial infections, vaccines directed against those infections and bacterial vaccines. More particularly, the invention relates to vaccines directed against Streptococcus infections in pigs. The invention provides a ?FolT mutant of a bacterium having reduced capacity to transport folate, wherein said capacity has been reduced by functionally deleting folate transporter (FolT) function. The invention also provides a method to reduce virulence of a bacterium comprising reducing the capacity of said bacterium to transport folate.

Abstract: The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.

Abstract: A new use of Lactobacillus paracasei subsp. paracasei K56 capable of regulating the gastrointestinal flora balance is described. The deposit number of the Lactobacillus paracasei subsp. paracasei is DSM27447. This strain alone has the ability to significantly promote the growth of intestinal Bifidobacterium and Lactobacillus, suppress Desulfovibrio and/or Enterobacteria in the intestine, suppress Helicobacter and/or Escherichia-Shigella, and can endure a simulated in vitro gastrointestinal fluid stress environment. Experiments in mice show that this strain has no acute oral toxicity, no antibiotic resistance, and may be safely used in food processing.

Abstract: It is an object to provide a combination therapy effective in cancer immunotherapy. The object is achieved by providing an anti-tumor agent, including a transformed Bifidobacterium containing DNA encoding a WT1 protein and DNA encoding a GNB/LNB substrate-binding membrane protein derived from a Bifidobacterium, the transformed Bifidobacterium being designed to display the WT1 protein as an antigen on a surface of the transformed Bifidobacterium, the anti-tumor agent being for use in combination with an immunosuppression inhibitor. The transformed Bifidobacterium can be used as an oral tumor vaccine.